Breast Cancer



ESMO scale offers guidance on cancer targets

The ESMO Scale of Clinical Actionability for Molecular Targets is intended to help oncologists prioritize therapeutic targets detected on gene...

From the Journals

Variants in five genes signal TNBC risk

Risks for triple-negative breast cancer associated with pathogenic variants in five genes ranged from about 5.5-fold to nearly 17-fold.

From the Journals

RT linked with better survival in DCIS

Lumpectomy plus radiotherapy is associated with a significant reduction in breast cancer mortality versus lumpectomy or mastectomy alone.